{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T12:39:30Z","timestamp":1792931970669,"version":"4.5.0"},"reference-count":158,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-07151-5","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T10:22:09Z","timestamp":1761214929000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["CAR-T and CAR-NK cell therapies in AML: breaking barriers and charting the future"],"prefix":"10.1186","volume":"23","author":[{"given":"Huichao","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7769-8320","authenticated-orcid":false,"given":"Fatemeh Sadat","family":"Shafiei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7373-6092","authenticated-orcid":false,"given":"Zahra","family":"Taghinejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4559-6525","authenticated-orcid":false,"given":"Mohsen","family":"Maleknia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9755-2850","authenticated-orcid":false,"given":"Hanieh","family":"Noormohamadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1029-751X","authenticated-orcid":false,"given":"Atieh","family":"Raoufi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4863-2595","authenticated-orcid":false,"given":"Sina","family":"Nouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7120-9173","authenticated-orcid":false,"given":"Nazli","family":"Servatian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1045-7613","authenticated-orcid":false,"given":"Hamed","family":"Soleimani Samarkhazan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"issue":"10","key":"7151_CR1","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.3390\/cancers15102713","volume":"15","author":"E Atilla","year":"2023","unstructured":"Atilla E, Benabdellah K. The black hole: CAR T cell therapy in AML. Cancers (Basel). 2023;15(10):2713.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"7151_CR2","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1186\/s13287-021-02420-8","volume":"12","author":"F Marofi","year":"2021","unstructured":"Marofi F, et al. Novel CAR t therapy is a ray of hope in the treatment of seriously ill AML patients. Stem Cell Res Ther. 2021;12(1):465.","journal-title":"Stem Cell Res Ther"},{"key":"7151_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06387-x","author":"O Aval","year":"2025","unstructured":"Aval O, et al. Galectin-9: a double-edged sword in acute myeloid leukemia. Ann Hematol. 2025. https:\/\/doi.org\/10.1007\/s00277-025-06387-x.","journal-title":"Ann Hematol"},{"issue":"1","key":"7151_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s40364-023-00501-9","volume":"11","author":"R Shao","year":"2023","unstructured":"Shao R, et al. Biomarkers as targets for CAR-T\/NK cell therapy in AML. Biomark Res. 2023;11(1):65.","journal-title":"Biomark Res"},{"issue":"9","key":"7151_CR5","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000937","volume":"7","author":"J Vanhooren","year":"2023","unstructured":"Vanhooren J, et al. Car-T in the treatment of acute myeloid leukemia: barriers and how to overcome them. Hemasphere. 2023;7(9):e937.","journal-title":"Hemasphere"},{"key":"7151_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2025.104986","volume":"414","author":"I Ahmad","year":"2025","unstructured":"Ahmad I, et al. Mesenchymal stem cell-derived exosomes (MSC-exosomes) in hematology: from mechanisms to clinical breakthroughs. Cell Immunol. 2025;414:104986.","journal-title":"Cell Immunol"},{"issue":"6","key":"7151_CR7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00432-025-06244-4","volume":"151","author":"MJ Saadh","year":"2025","unstructured":"Saadh MJ, et al. Mesenchymal stem cells in the bone marrow microenvironment: a double-edged sword for AML. J Cancer Res Clin Oncol. 2025;151(6):193.","journal-title":"J Cancer Res Clin Oncol"},{"key":"7151_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14051241","author":"P Vishwasrao","year":"2022","unstructured":"Vishwasrao P, et al. Emerging CAR T cell strategies for the treatment of AML. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14051241.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"7151_CR9","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12967-021-02829-y","volume":"19","author":"O Clemente","year":"2021","unstructured":"Clemente O, et al. Is immunotherapy in the future of therapeutic management of sarcomas? J Transl Med. 2021;19(1):173.","journal-title":"J Transl Med"},{"issue":"4","key":"7151_CR10","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","volume":"38","author":"M Hong","year":"2020","unstructured":"Hong M, Clubb JD, Chen YY. Engineering CAR-T cells for next-generation cancer therapy. Cancer Cell. 2020;38(4):473\u201388.","journal-title":"Cancer Cell"},{"key":"7151_CR11","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3389\/fonc.2020.00262","volume":"10","author":"R Epperly","year":"2020","unstructured":"Epperly R, Gottschalk S, Velasquez MP. A bump in the road: how the hostile AML microenvironment affects CAR T cell therapy. Front Oncol. 2020;10:262.","journal-title":"Front Oncol"},{"issue":"1","key":"7151_CR12","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s11033-025-10527-x","volume":"52","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan H, et al. C-type lectin-like molecule-1 as a diagnostic, prognostic, and therapeutic marker in leukemia. Mol Biol Rep. 2025;52(1):464.","journal-title":"Mol Biol Rep"},{"key":"7151_CR13","doi-asserted-by":"publisher","first-page":"1361194","DOI":"10.3389\/fimmu.2024.1361194","volume":"15","author":"T Li","year":"2024","unstructured":"Li T, et al. CAR-NK cells for cancer immunotherapy: recent advances and future directions. Front Immunol. 2024;15:1361194.","journal-title":"Front Immunol"},{"issue":"9","key":"7151_CR14","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s41434-021-00246-w","volume":"28","author":"N Albinger","year":"2021","unstructured":"Albinger N, Hartmann J, Ullrich E. Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany. Gene Ther. 2021;28(9):513\u201327.","journal-title":"Gene Ther"},{"issue":"6","key":"7151_CR15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s12032-025-02742-0","volume":"42","author":"MJ Saadh","year":"2025","unstructured":"Saadh MJ, et al. Mesenchymal stem cell-derived exosomes: a novel therapeutic frontier in hematological disorders. Med Oncol. 2025;42(6):199.","journal-title":"Med Oncol"},{"issue":"1","key":"7151_CR16","first-page":"32","volume":"1","author":"Z Gao","year":"2025","unstructured":"Gao Z, et al. Heterogeneity of intratumoral microbiota within the tumor microenvironment and relationship to tumor development. Med Res. 2025;1(1):32\u201361.","journal-title":"Med Res"},{"issue":"1","key":"7151_CR17","first-page":"62","volume":"1","author":"G Li","year":"2025","unstructured":"Li G, et al. Breaking boundaries: chronic diseases and the frontiers of immune microenvironments. Med Res. 2025;1(1):62\u2013102.","journal-title":"Med Res"},{"issue":"1","key":"7151_CR18","doi-asserted-by":"publisher","first-page":"26","DOI":"10.2302\/kjm.ABSTRACT_72_1-1","volume":"72","author":"CH June","year":"2023","unstructured":"June CH. The unlikely development of CAR T cells: a brief history and prospects for the future. Keio J Med. 2023;72(1):26.","journal-title":"Keio J Med"},{"key":"7151_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15123081","author":"M Mez\u0151si-Csapl\u00e1r","year":"2023","unstructured":"Mez\u0151si-Csapl\u00e1r M, Sz\u00f6\u0151r \u00c1, Vereb G. CD28 and 41BB costimulatory domains alone or in combination differentially influence cell surface dynamics and organization of chimeric antigen receptors and early activation of CAR T cells. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15123081.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"7151_CR20","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s11912-023-01380-x","volume":"25","author":"G Guzman","year":"2023","unstructured":"Guzman G, et al. Car-T therapies in solid tumors: opportunities and challenges. Curr Oncol Rep. 2023;25(5):479\u201389.","journal-title":"Curr Oncol Rep"},{"key":"7151_CR21","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aat6753","author":"AI Salter","year":"2018","unstructured":"Salter AI, et al. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. Sci Signal. 2018. https:\/\/doi.org\/10.1126\/scisignal.aat6753.","journal-title":"Sci Signal"},{"key":"7151_CR22","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.omtm.2018.12.009","volume":"12","author":"S Guedan","year":"2019","unstructured":"Guedan S, et al. Engineering and design of chimeric antigen receptors. Mol Ther Methods Clin Dev. 2019;12:145\u201356.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"7151_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2020.00312","volume":"11","author":"RY Alhabbab","year":"2020","unstructured":"Alhabbab RY. Targeting cancer stem cells by genetically engineered chimeric antigen receptor T cells. Front Genet. 2020;11:312.","journal-title":"Front Genet"},{"issue":"2","key":"7151_CR24","first-page":"674","volume":"10","author":"M Chulanetra","year":"2020","unstructured":"Chulanetra M, et al. Gd2 chimeric antigen receptor modified T cells in synergy with sub-toxic level of doxorubicin targeting osteosarcomas. Am J Cancer Res. 2020;10(2):674\u201387.","journal-title":"Am J Cancer Res"},{"issue":"1","key":"7151_CR25","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3390\/ijms23010405","volume":"23","author":"E Guerra","year":"2021","unstructured":"Guerra E, et al. Cancer-homing CAR-T cells and endogenous immune population dynamics. Int J Mol Sci. 2021;23(1):405.","journal-title":"Int J Mol Sci"},{"key":"7151_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/cells10123376","author":"F Hao","year":"2021","unstructured":"Hao F, et al. The role of T cell immunotherapy in acute myeloid leukemia. Cells. 2021. https:\/\/doi.org\/10.3390\/cells10123376.","journal-title":"Cells"},{"issue":"2","key":"7151_CR27","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1053\/j.seminhematol.2018.08.008","volume":"56","author":"KD Cummins","year":"2019","unstructured":"Cummins KD, Gill S. Will CAR T cell therapy have a role in AML? Promises and pitfalls. Semin Hematol. 2019;56(2):155\u201363.","journal-title":"Semin Hematol"},{"issue":"1","key":"7151_CR28","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s11033-024-10200-9","volume":"52","author":"L Rajabi","year":"2025","unstructured":"Rajabi L, et al. Aqueous and ethanolic extracts of Moringa oleifera leaves induce selective cytotoxicity in Raji and Jurkat cell lines by activating the P21 pathway independent of P53. Mol Biol Rep. 2025;52(1):102.","journal-title":"Mol Biol Rep"},{"issue":"1","key":"7151_CR29","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3390\/cancers15010253","volume":"15","author":"D Damiani","year":"2022","unstructured":"Damiani D, Tiribelli M. Present and future role of immune targets in acute myeloid leukemia. Cancers. 2022;15(1):253.","journal-title":"Cancers"},{"issue":"1","key":"7151_CR30","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s40364-025-00786-y","volume":"13","author":"S Zehtabcheh","year":"2025","unstructured":"Zehtabcheh S, et al. Insights into KMT2A rearrangements in acute myeloid leukemia: from molecular characteristics to targeted therapies. Biomark Res. 2025;13(1):73.","journal-title":"Biomark Res"},{"issue":"1","key":"7151_CR31","doi-asserted-by":"publisher","first-page":"10","DOI":"10.5045\/br.2020.55.1.10","volume":"55","author":"E Fathi","year":"2020","unstructured":"Fathi E, et al. A general view of CD33(+) leukemic stem cells and CAR-T cells as interesting targets in acute myeloblatsic leukemia therapy. Blood Res. 2020;55(1):10\u20136.","journal-title":"Blood Res"},{"issue":"6","key":"7151_CR32","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1038\/s41375-018-0075-3","volume":"32","author":"JC Petrov","year":"2018","unstructured":"Petrov JC, et al. Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia. Leukemia. 2018;32(6):1317\u201326.","journal-title":"Leukemia"},{"issue":"5","key":"7151_CR33","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1200\/JCO.20.00475","volume":"39","author":"S Khaldoyanidi","year":"2021","unstructured":"Khaldoyanidi S, et al. Immune biology of acute myeloid leukemia: implications for immunotherapy. J Clin Oncol. 2021;39(5):419.","journal-title":"J Clin Oncol"},{"issue":"3","key":"7151_CR34","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020;17(3):147\u201367.","journal-title":"Nat Rev Clin Oncol"},{"key":"7151_CR35","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3389\/fonc.2020.00697","volume":"10","author":"S Mardiana","year":"2020","unstructured":"Mardiana S, Gill S. CAR t cells for acute myeloid leukemia: state of the art and future directions. Front Oncol. 2020;10:697.","journal-title":"Front Oncol"},{"issue":"10","key":"7151_CR36","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1016\/j.ymthe.2018.08.001","volume":"26","author":"S John","year":"2018","unstructured":"John S, et al. A novel anti-LILRB4 CAR-T cell for the treatment of monocytic AML. Mol Ther. 2018;26(10):2487\u201395.","journal-title":"Mol Ther"},{"issue":"12","key":"7151_CR37","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1002\/cam4.522","volume":"4","author":"T Guery","year":"2015","unstructured":"Guery T, et al. B7\u2013H3 protein expression in acute myeloid leukemia. Cancer Med. 2015;4(12):1879\u201383.","journal-title":"Cancer Med"},{"issue":"2","key":"7151_CR38","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1084\/jem.20152008","volume":"214","author":"C Riether","year":"2017","unstructured":"Riether C, et al. CD70\/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia. J Exp Med. 2017;214(2):359\u201380.","journal-title":"J Exp Med"},{"issue":"4","key":"7151_CR39","doi-asserted-by":"publisher","first-page":"608","DOI":"10.3390\/hematolrep15040063","volume":"15","author":"S Garg","year":"2023","unstructured":"Garg S, et al. Chimeric antigen receptor T cell therapy in acute myeloid leukemia: trials and tribulations. Hematol Rep. 2023;15(4):608\u201326.","journal-title":"Hematol Rep"},{"issue":"2","key":"7151_CR40","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41388-020-01501-x","volume":"40","author":"M Poorebrahim","year":"2021","unstructured":"Poorebrahim M, et al. Counteracting CAR T cell dysfunction. Oncogene. 2021;40(2):421\u201335.","journal-title":"Oncogene"},{"issue":"5","key":"7151_CR41","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1158\/2326-6066.CIR-18-0466","volume":"7","author":"D Alizadeh","year":"2019","unstructured":"Alizadeh D, et al. IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype. Cancer Immunol Res. 2019;7(5):759\u201372.","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"7151_CR42","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1182\/blood.2023022293","volume":"144","author":"BD Ng","year":"2024","unstructured":"Ng BD, et al. IL-18-secreting multiantigen targeting CAR T cells eliminate antigen-low myeloma in an immunocompetent mouse model. Blood. 2024;144(2):171\u201386.","journal-title":"Blood"},{"issue":"4","key":"7151_CR43","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s41587-019-0398-2","volume":"38","author":"X Ma","year":"2020","unstructured":"Ma X, et al. Interleukin-23 engineering improves CAR T cell function in solid tumors. Nat Biotechnol. 2020;38(4):448\u201359.","journal-title":"Nat Biotechnol"},{"issue":"10","key":"7151_CR44","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s00262-024-03756-9","volume":"73","author":"H Wu","year":"2024","unstructured":"Wu H, et al. Interleukin-7 expression by CAR-T cells improves CAR-T cell survival and efficacy in chordoma. Cancer Immunol Immunother. 2024;73(10):188.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"7151_CR45","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","volume":"120","author":"N Tokarew","year":"2019","unstructured":"Tokarew N, et al. Teaching an old dog new tricks: next-generation CAR T cells. Br J Cancer. 2019;120(1):26\u201337.","journal-title":"Br J Cancer"},{"issue":"6","key":"7151_CR46","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2114254","volume":"18","author":"T Asmamaw Dejenie","year":"2022","unstructured":"Asmamaw Dejenie T, et al. Current updates on generations, approvals, and clinical trials of CAR T-cell therapy. Hum Vaccin Immunother. 2022;18(6):2114254.","journal-title":"Hum Vaccin Immunother"},{"key":"7151_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112816","author":"IM Michelozzi","year":"2021","unstructured":"Michelozzi IM, Kirtsios E, Giustacchini A. Driving CAR T stem cell targeting in acute myeloid leukemia: the roads to success. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13112816.","journal-title":"Cancers (Basel)"},{"issue":"12","key":"7151_CR48","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1038\/nm1676","volume":"13","author":"MT Stephan","year":"2007","unstructured":"Stephan MT, et al. T cell\u2013encoded CD80 and 4\u20131BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med. 2007;13(12):1440\u20139.","journal-title":"Nat Med"},{"issue":"3","key":"7151_CR49","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/imm.12784","volume":"152","author":"A Lynch","year":"2017","unstructured":"Lynch A, et al. Adoptive transfer of murine T cells expressing a chimeric-PD1-Dap10 receptor as an immunotherapy for lymphoma. Immunology. 2017;152(3):472\u201383.","journal-title":"Immunology"},{"issue":"7","key":"7151_CR50","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","volume":"26","author":"CC Kloss","year":"2018","unstructured":"Kloss CC, et al. Dominant-negative TGF-\u03b2 receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication. Mol Ther. 2018;26(7):1855\u201366.","journal-title":"Mol Ther"},{"key":"7151_CR51","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008275","author":"A Pievani","year":"2024","unstructured":"Pievani A, et al. CARs are sharpening their weapons. J Immunother Cancer. 2024. https:\/\/doi.org\/10.1136\/jitc-2023-008275.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"7151_CR52","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-15-2524","volume":"76","author":"X Liu","year":"2016","unstructured":"Liu X, et al. A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors. Cancer Res. 2016;76(6):1578\u201390.","journal-title":"Cancer Res"},{"issue":"3","key":"7151_CR53","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.molimm.2012.03.023","volume":"51","author":"ME Prosser","year":"2012","unstructured":"Prosser ME, et al. Tumor PD-L1 co-stimulates primary human CD8+ cytotoxic T cells modified to express a PD1:CD28 chimeric receptor. Mol Immunol. 2012;51(3):263\u201372.","journal-title":"Mol Immunol"},{"key":"7151_CR54","doi-asserted-by":"publisher","first-page":"1034707","DOI":"10.3389\/fimmu.2022.1034707","volume":"13","author":"J Tomasik","year":"2022","unstructured":"Tomasik J, Jasi\u0144ski M, Basak GW. Next generations of CAR-T cells - new therapeutic opportunities in hematology? Front Immunol. 2022;13:1034707.","journal-title":"Front Immunol"},{"issue":"1","key":"7151_CR55","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10238-025-01764-2","volume":"25","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan H, et al. Targeting acute myeloid leukemia through antibody engineering: innovations in immunotherapy and combination regimens. Clin Exp Med. 2025;25(1):215.","journal-title":"Clin Exp Med"},{"issue":"1","key":"7151_CR56","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s10238-025-01795-9","volume":"25","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan H, et al. The AML immune paradox: decoding escape pathways and pioneering checkpoint, vaccine, and combination strategies. Clin Exp Med. 2025;25(1):240.","journal-title":"Clin Exp Med"},{"issue":"16","key":"7151_CR57","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1182\/blood.2022016101","volume":"141","author":"MM Dacek","year":"2023","unstructured":"Dacek MM, et al. Potentiating antibody-dependent killing of cancers with CAR T cells secreting CD47-SIRP\u03b1 checkpoint blocker. Blood. 2023;141(16):2003\u201315.","journal-title":"Blood"},{"issue":"5","key":"7151_CR58","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","volume":"36","author":"R Grosser","year":"2019","unstructured":"Grosser R, et al. Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell. 2019;36(5):471\u201382.","journal-title":"Cancer Cell"},{"key":"7151_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10111845","author":"S Michaelides","year":"2022","unstructured":"Michaelides S, et al. Migratory engineering of T cells for cancer therapy. Vaccines. 2022. https:\/\/doi.org\/10.3390\/vaccines10111845.","journal-title":"Vaccines"},{"issue":"Supplement 1","key":"7151_CR60","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1182\/blood-2022-163130","volume":"140","author":"M Biondi","year":"2022","unstructured":"Biondi M, et al. Overexpression of CXCR4 enhances the efficacy of CAR-T therapy for acute myeloid leukemia. Blood. 2022;140(Supplement 1):4500\u20131.","journal-title":"Blood"},{"key":"7151_CR61","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.3389\/fonc.2020.01672","volume":"10","author":"D Cancilla","year":"2020","unstructured":"Cancilla D, Rettig MP, DiPersio JF. Targeting CXCR4 in AML and ALL. Front Oncol. 2020;10:1672.","journal-title":"Front Oncol"},{"issue":"374","key":"7151_CR62","doi-asserted-by":"publisher","first-page":"eaaj2013","DOI":"10.1126\/scitranslmed.aaj2013","volume":"9","author":"W Qasim","year":"2017","unstructured":"Qasim W, et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med. 2017;9(374):eaaj2013.","journal-title":"Sci Transl Med"},{"issue":"6","key":"7151_CR63","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20(6):359\u201371.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"7151_CR64","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/s12935-024-03479-y","volume":"24","author":"S Mansoori","year":"2024","unstructured":"Mansoori S, et al. Recent updates on allogeneic CAR-T cells in hematological malignancies. Cancer Cell Int. 2024;24(1):304.","journal-title":"Cancer Cell Int"},{"issue":"18","key":"7151_CR65","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","volume":"365","author":"AD Stasi","year":"2011","unstructured":"Stasi AD, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011;365(18):1673\u201383.","journal-title":"N Engl J Med"},{"issue":"5","key":"7151_CR66","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1182\/blood-2011-02-337360","volume":"118","author":"X Wang","year":"2011","unstructured":"Wang X, et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood. 2011;118(5):1255\u201363.","journal-title":"Blood"},{"issue":"9","key":"7151_CR67","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.3324\/haematol.2008.001677","volume":"94","author":"G Marieke","year":"2009","unstructured":"Marieke G, et al. Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy. Haematologica. 2009;94(9):1316\u201320.","journal-title":"Haematologica"},{"issue":"6","key":"7151_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101070","volume":"14","author":"E Moghanloo","year":"2021","unstructured":"Moghanloo E, et al. Remote controlling of CAR-T cells and toxicity management: molecular switches and next generation CARs. Transl Oncol. 2021;14(6):101070.","journal-title":"Transl Oncol"},{"issue":"3","key":"7151_CR69","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jcyt.2021.10.007","volume":"24","author":"PA Atilla","year":"2022","unstructured":"Atilla PA, et al. Combinatorial antigen targeting strategies for acute leukemia: application in myeloid malignancy. Cytotherapy. 2022;24(3):282\u201390.","journal-title":"Cytotherapy"},{"issue":"1","key":"7151_CR70","doi-asserted-by":"publisher","first-page":"2248826","DOI":"10.1080\/2162402X.2023.2248826","volume":"12","author":"X Jin","year":"2023","unstructured":"Jin X, et al. CAR-T cells dual-target CD123 and NKG2DLs to eradicate AML cells and selectively target immunosuppressive cells. Oncoimmunology. 2023;12(1):2248826.","journal-title":"Oncoimmunology"},{"issue":"1","key":"7151_CR71","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40364-025-00738-6","volume":"13","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan H, et al. Unveiling the potential of CLL-1: a promising target for AML therapy. Biomark Res. 2025;13(1):28.","journal-title":"Biomark Res"},{"issue":"2","key":"7151_CR72","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/bjh.17186","volume":"193","author":"H Rafei","year":"2021","unstructured":"Rafei H, Daher M, Rezvani K. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity. Br J Haematol. 2021;193(2):216\u201330.","journal-title":"Br J Haematol"},{"issue":"5","key":"7151_CR73","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41423-019-0206-4","volume":"16","author":"S Sivori","year":"2019","unstructured":"Sivori S, et al. Human NK cells: surface receptors, inhibitory checkpoints, and translational applications. Cell Mol Immunol. 2019;16(5):430\u201341.","journal-title":"Cell Mol Immunol"},{"issue":"9","key":"7151_CR74","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1084\/jem.20181454","volume":"216","author":"I Prager","year":"2019","unstructured":"Prager I, et al. NK cells switch from granzyme B to death receptor-mediated cytotoxicity during serial killing. J Exp Med. 2019;216(9):2113\u201327.","journal-title":"J Exp Med"},{"issue":"1","key":"7151_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12094-019-02132-9","volume":"22","author":"M Maleknia","year":"2020","unstructured":"Maleknia M, et al. Immunomodulation in leukemia: cellular aspects of anti-leukemic properties. Clin Transl Oncol. 2020;22(1):1\u201310.","journal-title":"Clin Transl Oncol"},{"key":"7151_CR76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.732135","volume":"12","author":"EL Heipertz","year":"2021","unstructured":"Heipertz EL, et al. Current perspectives on \u201coff-the-shelf\u201d allogeneic NK and CAR-NK cell therapies. Front Immunol. 2021;12:732135.","journal-title":"Front Immunol"},{"issue":"1","key":"7151_CR77","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13045-021-01083-5","volume":"14","author":"Y Gong","year":"2021","unstructured":"Gong Y, et al. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. J Hematol Oncol. 2021;14(1):73.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"7151_CR78","first-page":"1083","volume":"8","author":"X Tang","year":"2018","unstructured":"Tang X, et al. First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am J Cancer Res. 2018;8(6):1083\u20139.","journal-title":"Am J Cancer Res"},{"issue":"17","key":"7151_CR79","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1182\/blood-2016-01-689976","volume":"127","author":"G Olombel","year":"2016","unstructured":"Olombel G, et al. The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia. Blood. 2016;127(17):2157\u201360.","journal-title":"Blood"},{"issue":"4","key":"7151_CR80","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41408-022-00660-2","volume":"12","author":"N Albinger","year":"2022","unstructured":"Albinger N, et al. Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia. Blood Cancer J. 2022;12(4):61.","journal-title":"Blood Cancer J"},{"issue":"1","key":"7151_CR81","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13045-022-01376-3","volume":"15","author":"S Caruso","year":"2022","unstructured":"Caruso S, et al. Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia. J Hematol Oncol. 2022;15(1):163.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"7151_CR82","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3324\/haematol.2020.271908","volume":"107","author":"M Gurney","year":"2022","unstructured":"Gurney M, et al. CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide. Haematologica. 2022;107(2):437\u201345.","journal-title":"Haematologica"},{"issue":"1","key":"7151_CR83","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40164-025-00633-8","volume":"14","author":"LV J\u00f8rgensen","year":"2025","unstructured":"J\u00f8rgensen LV, et al. The clinical landscape of CAR NK cells. Exp Hematol Oncol. 2025;14(1):46.","journal-title":"Exp Hematol Oncol"},{"key":"7151_CR84","doi-asserted-by":"publisher","DOI":"10.3390\/v13071365","author":"MA Morgan","year":"2021","unstructured":"Morgan MA, et al. Improved activity against acute myeloid leukemia with chimeric antigen receptor (CAR)-NK-92 cells designed to target CD123. Viruses. 2021. https:\/\/doi.org\/10.3390\/v13071365.","journal-title":"Viruses"},{"issue":"12","key":"7151_CR85","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1038\/s41590-023-01659-y","volume":"24","author":"OK Dagher","year":"2023","unstructured":"Dagher OK, Posey AD Jr. Forks in the road for CAR T and CAR NK cell cancer therapies. Nat Immunol. 2023;24(12):1994\u20132007.","journal-title":"Nat Immunol"},{"issue":"5","key":"7151_CR86","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/bjh.17544","volume":"195","author":"K Sanber","year":"2021","unstructured":"Sanber K, Savani B, Jain T. Graft-versus-host disease risk after chimeric antigen receptor T-cell therapy: the diametric opposition of T cells. Br J Haematol. 2021;195(5):660\u20138.","journal-title":"Br J Haematol"},{"issue":"1","key":"7151_CR87","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s10238-025-01588-0","volume":"25","author":"A Raoufi","year":"2025","unstructured":"Raoufi A, et al. Macrophages in graft-versus-host disease (GVHD): dual roles as therapeutic tools and targets. Clin Exp Med. 2025;25(1):73.","journal-title":"Clin Exp Med"},{"key":"7151_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117024","volume":"177","author":"M Bahramloo","year":"2024","unstructured":"Bahramloo M, et al. CAR-NK cell therapy in AML: current treatment, challenges, and advantage. Biomed Pharmacother. 2024;177:117024.","journal-title":"Biomed Pharmacother"},{"key":"7151_CR89","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15082323","author":"Y Yu","year":"2023","unstructured":"Yu Y. The function of NK cells in tumor metastasis and NK cell-based immunotherapy. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15082323.","journal-title":"Cancers (Basel)"},{"key":"7151_CR90","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01869","volume":"9","author":"AM Abel","year":"2018","unstructured":"Abel AM, et al. Natural killer cells: development, maturation, and clinical utilization. Front Immunol. 2018;9:1869.","journal-title":"Front Immunol"},{"issue":"17","key":"7151_CR91","doi-asserted-by":"publisher","first-page":"4318","DOI":"10.3390\/cancers14174318","volume":"14","author":"Z Pang","year":"2022","unstructured":"Pang Z, et al. Current progress of CAR-NK therapy in cancer treatment. Cancers (Basel). 2022;14(17):4318.","journal-title":"Cancers (Basel)"},{"key":"7151_CR92","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.omtm.2020.06.014","volume":"18","author":"Y Yang","year":"2020","unstructured":"Yang Y, et al. Superior expansion and cytotoxicity of human primary NK and CAR-NK cells from various sources via enriched metabolic pathways. Mol Ther Methods Clin Dev. 2020;18:428\u201345.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"7151_CR93","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.626098","volume":"12","author":"E Liu","year":"2021","unstructured":"Liu E, et al. GMP-compliant universal antigen presenting cells (uAPC) promote the metabolic fitness and antitumor activity of armored cord blood CAR-NK cells. Front Immunol. 2021;12:626098.","journal-title":"Front Immunol"},{"key":"7151_CR94","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.803380","volume":"13","author":"CDL Johnson","year":"2022","unstructured":"Johnson CDL, et al. Feeder-cell-free and serum-free expansion of natural killer cells using Cloudz microspheres, G-Rex6M, and human platelet lysate. Front Immunol. 2022;13:803380.","journal-title":"Front Immunol"},{"issue":"16","key":"7151_CR95","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1182\/blood.2021010858","volume":"138","author":"KP Micklethwaite","year":"2021","unstructured":"Micklethwaite KP, et al. Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells. Blood. 2021;138(16):1391\u2013405.","journal-title":"Blood"},{"key":"7151_CR96","doi-asserted-by":"publisher","DOI":"10.3390\/v13081528","author":"RP Labb\u00e9","year":"2021","unstructured":"Labb\u00e9 RP, Vessillier S, Rafiq QA. Lentiviral vectors for T cell engineering: clinical applications, bioprocessing and future perspectives. Viruses. 2021. https:\/\/doi.org\/10.3390\/v13081528.","journal-title":"Viruses"},{"key":"7151_CR97","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02873","volume":"10","author":"ABL Colamartino","year":"2019","unstructured":"Colamartino ABL, et al. Efficient and robust NK-cell transduction with baboon envelope pseudotyped lentivector. Front Immunol. 2019;10:2873.","journal-title":"Front Immunol"},{"key":"7151_CR98","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.953849","volume":"13","author":"A Valeri","year":"2022","unstructured":"Valeri A, et al. Overcoming tumor resistance mechanisms in CAR-NK cell therapy. Front Immunol. 2022;13:953849.","journal-title":"Front Immunol"},{"key":"7151_CR99","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040893","author":"C Sordo-Bahamonde","year":"2020","unstructured":"Sordo-Bahamonde C, et al. Mechanisms of resistance to NK cell immunotherapy. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12040893.","journal-title":"Cancers (Basel)"},{"issue":"23","key":"7151_CR100","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1182\/blood.2021015184","volume":"140","author":"F Cichocki","year":"2022","unstructured":"Cichocki F, et al. Dual antigen-targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia. Blood. 2022;140(23):2451\u201362.","journal-title":"Blood"},{"issue":"2","key":"7151_CR101","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","volume":"23","author":"Y Li","year":"2018","unstructured":"Li Y, et al. Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity. Cell Stem Cell. 2018;23(2):181-192.e5.","journal-title":"Cell Stem Cell"},{"key":"7151_CR102","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2015.00021","volume":"6","author":"W Glienke","year":"2015","unstructured":"Glienke W, et al. Advantages and applications of CAR-expressing natural killer cells. Front Pharmacol. 2015;6:21.","journal-title":"Front Pharmacol"},{"key":"7151_CR103","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.755639","volume":"12","author":"M Guercio","year":"2021","unstructured":"Guercio M, et al. Inclusion of the inducible Caspase 9 suicide gene in CAR construct increases safety of CAR.CD19 T cell therapy in B-cell malignancies. Front Immunol. 2021;12:755639.","journal-title":"Front Immunol"},{"issue":"2","key":"7151_CR104","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1158\/2326-6066.CIR-20-1023","volume":"10","author":"M Klopotowska","year":"2022","unstructured":"Klopotowska M, et al. PRDX-1 supports the survival and antitumor activity of primary and CAR-modified NK cells under oxidative stress. Cancer Immunol Res. 2022;10(2):228\u201344.","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"7151_CR105","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.molcel.2020.05.034","volume":"78","author":"JE Bader","year":"2020","unstructured":"Bader JE, Voss K, Rathmell JC. Targeting metabolism to improve the tumor microenvironment for cancer immunotherapy. Mol Cell. 2020;78(6):1019\u201333.","journal-title":"Mol Cell"},{"issue":"1","key":"7151_CR106","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1158\/2159-8290.CD-20-0556","volume":"11","author":"M Daher","year":"2021","unstructured":"Daher M, Rezvani K. Outlook for new CAR-based therapies with a focus on CAR NK cells: what lies beyond CAR-engineered T cells in the race against cancer. Cancer Discov. 2021;11(1):45\u201358.","journal-title":"Cancer Discov"},{"issue":"5","key":"7151_CR107","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1172\/JCI123955","volume":"129","author":"T Kamiya","year":"2019","unstructured":"Kamiya T, et al. Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells. J Clin Invest. 2019;129(5):2094\u2013106.","journal-title":"J Clin Invest"},{"key":"7151_CR108","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232112828","author":"G Ure\u00f1a-Bail\u00e9n","year":"2022","unstructured":"Ure\u00f1a-Bail\u00e9n G, et al. Preclinical evaluation of CRISPR-edited CAR-NK-92 cells for off-the-shelf treatment of AML and B-ALL. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms232112828.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"7151_CR109","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1182\/blood-2004-12-4797","volume":"106","author":"C Imai","year":"2005","unstructured":"Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood. 2005;106(1):376\u201383.","journal-title":"Blood"},{"issue":"5","key":"7151_CR110","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1182\/blood.2020007748","volume":"137","author":"M Daher","year":"2021","unstructured":"Daher M, et al. Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. Blood. 2021;137(5):624\u201336.","journal-title":"Blood"},{"key":"7151_CR111","doi-asserted-by":"publisher","first-page":"7855808","DOI":"10.1155\/2021\/7855808","volume":"2021","author":"A MacDonald","year":"2021","unstructured":"MacDonald A, Wu TC, Hung CF. Interleukin 2-Based Fusion Proteins for the Treatment of Cancer. J Immunol Res. 2021;2021:7855808.","journal-title":"J Immunol Res"},{"key":"7151_CR112","doi-asserted-by":"publisher","DOI":"10.3390\/cells13050451","author":"A Maia","year":"2024","unstructured":"Maia A, et al. Building a better defense: expanding and improving natural killer cells for adoptive cell therapy. Cells. 2024. https:\/\/doi.org\/10.3390\/cells13050451.","journal-title":"Cells"},{"issue":"8000","key":"7151_CR113","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-023-06945-1","volume":"626","author":"E Vivier","year":"2024","unstructured":"Vivier E, et al. Natural killer cell therapies. Nature. 2024;626(8000):727\u201336.","journal-title":"Nature"},{"issue":"12","key":"7151_CR114","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1038\/s43018-022-00476-w","volume":"3","author":"L Brunello","year":"2022","unstructured":"Brunello L. Avoiding CAR-NK cell fratricide. Nat Cancer. 2022;3(12):1445.","journal-title":"Nat Cancer"},{"issue":"10","key":"7151_CR115","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-022-02003-x","volume":"28","author":"Y Li","year":"2022","unstructured":"Li Y, et al. KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape. Nat Med. 2022;28(10):2133\u201344.","journal-title":"Nat Med"},{"key":"7151_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117252","volume":"178","author":"H Lin","year":"2024","unstructured":"Lin H, et al. Antigen escape in CAR-T cell therapy: mechanisms and overcoming strategies. Biomed Pharmacother. 2024;178:117252.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"7151_CR117","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11899-023-00687-7","volume":"18","author":"KL Chohan","year":"2023","unstructured":"Chohan KL, Siegler EL, Kenderian SS. CAR-t cell therapy: the efficacy and toxicity balance. Curr Hematol Malig Rep. 2023;18(2):9\u201318.","journal-title":"Curr Hematol Malig Rep"},{"issue":"1","key":"7151_CR118","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s11033-025-10692-z","volume":"52","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan H, et al. Curcumin and acute myeloid leukemia: a golden hope, updated insights. Mol Biol Rep. 2025;52(1):583.","journal-title":"Mol Biol Rep"},{"issue":"6","key":"7151_CR119","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","volume":"173","author":"MY Kim","year":"2018","unstructured":"Kim MY, et al. Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia. Cell. 2018;173(6):1439-1453.e19.","journal-title":"Cell"},{"key":"7151_CR120","doi-asserted-by":"publisher","DOI":"10.3390\/cells13181596","author":"E Bartoszewska","year":"2024","unstructured":"Bartoszewska E, et al. Overcoming antigen escape and T-cell exhaustion in CAR-T therapy for leukemia. Cells. 2024. https:\/\/doi.org\/10.3390\/cells13181596.","journal-title":"Cells"},{"issue":"22","key":"7151_CR121","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252212223","volume":"25","author":"J Wang","year":"2024","unstructured":"Wang J, et al. Metabolic reprogramming of immune cells in the tumor microenvironment. Int J Mol Sci. 2024;25(22):12223.","journal-title":"Int J Mol Sci"},{"key":"7151_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.genrep.2024.101979","volume":"36","author":"H Park","year":"2024","unstructured":"Park H, et al. Chimeric antigen receptor T-cell therapy in acute myeloid leukaemia: novel therapeutic approaches to longstanding challenges. Gene Rep. 2024;36:101979.","journal-title":"Gene Rep"},{"key":"7151_CR123","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.01.035","author":"M Khalifeh","year":"2025","unstructured":"Khalifeh M, Salman H. Engineering resilient CAR T cells for immunosuppressive environment. Mol Ther. 2025. https:\/\/doi.org\/10.1016\/j.ymthe.2025.01.035.","journal-title":"Mol Ther"},{"key":"7151_CR124","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.1034257","volume":"10","author":"X Zhu","year":"2022","unstructured":"Zhu X, Li Q, Zhu X. Mechanisms of CAR T cell exhaustion and current counteraction strategies. Front Cell Dev Biol. 2022;10:1034257.","journal-title":"Front Cell Dev Biol"},{"key":"7151_CR125","doi-asserted-by":"publisher","first-page":"1574742","DOI":"10.3389\/fimmu.2025.1574742","volume":"16","author":"S Balkhi","year":"2025","unstructured":"Balkhi S, et al. CAR-NK cell therapy: promise and challenges in solid tumors. Front Immunol. 2025;16:1574742.","journal-title":"Front Immunol"},{"issue":"5","key":"7151_CR126","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1158\/2643-3230.BCD-21-0084","volume":"2","author":"M Abou-El-Enein","year":"2021","unstructured":"Abou-El-Enein M, et al. Scalable manufacturing of CAR T cells for cancer immunotherapy. Blood Cancer Discov. 2021;2(5):408\u201322.","journal-title":"Blood Cancer Discov"},{"key":"7151_CR127","doi-asserted-by":"publisher","first-page":"732135","DOI":"10.3389\/fimmu.2021.732135","volume":"12","author":"EL Heipertz","year":"2021","unstructured":"Heipertz EL, et al. Current perspectives on \u201coff-the-shelf\u201d allogeneic NK and CAR-NK cell therapies. Front Immunol. 2021;12:732135.","journal-title":"Front Immunol"},{"issue":"8","key":"7151_CR128","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.jval.2024.04.004","volume":"27","author":"K Thavorn","year":"2024","unstructured":"Thavorn K, et al. Economic evaluations of chimeric antigen receptor T-cell therapies for hematologic and solid malignancies: a systematic review. Value Health. 2024;27(8):1149\u201373.","journal-title":"Value Health"},{"issue":"7","key":"7151_CR129","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/jnci\/djy193","volume":"111","author":"RR Sarkar","year":"2019","unstructured":"Sarkar RR, et al. Cost-effectiveness of chimeric antigen receptor T-cell therapy in pediatric relapsed\/refractory B-cell acute lymphoblastic leukemia. J Natl Cancer Inst. 2019;111(7):719\u201326.","journal-title":"J Natl Cancer Inst"},{"issue":"35","key":"7151_CR130","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/JCO.21.01992","volume":"39","author":"BD Santomasso","year":"2021","unstructured":"Santomasso BD, et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. J Clin Oncol. 2021;39(35):3978\u201392.","journal-title":"J Clin Oncol"},{"key":"7151_CR131","unstructured":"Soleimani Samarkhazan, H., et al., Nanosensors in Leukemia management: pioneering real-time biomarker detection for precision oncology. Nano Select. n\/a(n\/a), e70039"},{"key":"7151_CR132","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.798087","author":"M Hejazi","year":"2022","unstructured":"Hejazi M, et al. CD33 delineates two functionally distinct NK cell populations divergent in cytokine production and antibody-mediated cellular cytotoxicity. Front Immunol. 2022. https:\/\/doi.org\/10.3389\/fimmu.2021.798087.","journal-title":"Front Immunol"},{"issue":"2","key":"7151_CR133","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris EC, et al. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22(2):85\u201396.","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"7151_CR134","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust J, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7(12):1404\u201319.","journal-title":"Cancer Discov"},{"key":"7151_CR135","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.745320","volume":"12","author":"PF Caimi","year":"2021","unstructured":"Caimi PF, et al. Prophylactic tocilizumab prior to anti-CD19 CAR-T cell therapy for non-hodgkin lymphoma. Front Immunol. 2021;12:745320.","journal-title":"Front Immunol"},{"key":"7151_CR136","doi-asserted-by":"publisher","first-page":"1600411","DOI":"10.3389\/fimmu.2025.1600411","volume":"16","author":"C Hu","year":"2025","unstructured":"Hu C, et al. Application and prospects of genetic engineering in CAR-NK cell therapy. Front Immunol. 2025;16:1600411.","journal-title":"Front Immunol"},{"issue":"7","key":"7151_CR137","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.jtct.2023.04.001","volume":"29","author":"N Gazeau","year":"2023","unstructured":"Gazeau N, et al. Anakinra for refractory cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy. Transplant Cell Ther. 2023;29(7):430\u20137.","journal-title":"Transplant Cell Ther"},{"key":"7151_CR138","doi-asserted-by":"publisher","DOI":"10.3390\/jpm15020049","author":"MJ Hochman","year":"2025","unstructured":"Hochman MJ, Muniz JP, Papadantonakis N. Precision medicine in myeloid neoplasia: challenges and opportunities. J Pers Med. 2025. https:\/\/doi.org\/10.3390\/jpm15020049.","journal-title":"J Pers Med"},{"issue":"1","key":"7151_CR139","first-page":"1","volume":"3","author":"M Farrokhi","year":"2023","unstructured":"Farrokhi M, et al. Role of precision medicine and personalized medicine in the treatment of diseases. Kindle. 2023;3(1):1\u2013164.","journal-title":"Kindle"},{"issue":"3","key":"7151_CR140","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1009883","volume":"18","author":"A Naghizadeh","year":"2022","unstructured":"Naghizadeh A, et al. In vitro machine learning-based CAR T immunological synapse quality measurements correlate with patient clinical outcomes. PLoS Comput Biol. 2022;18(3):e1009883.","journal-title":"PLoS Comput Biol"},{"issue":"1","key":"7151_CR141","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s10238-025-01686-z","volume":"25","author":"AK Bishoyi","year":"2025","unstructured":"Bishoyi AK, et al. Nanotechnology in leukemia therapy: revolutionizing targeted drug delivery and immune modulation. Clin Exp Med. 2025;25(1):166.","journal-title":"Clin Exp Med"},{"issue":"1","key":"7151_CR142","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s10238-025-01724-w","volume":"25","author":"A Bayani","year":"2025","unstructured":"Bayani A, et al. Aptamer-based approaches in leukemia: a paradigm shift in targeted therapy. Clin Exp Med. 2025;25(1):186.","journal-title":"Clin Exp Med"},{"issue":"11","key":"7151_CR143","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1182\/blood.2024024063","volume":"145","author":"S Haubner","year":"2025","unstructured":"Haubner S, Subklewe M, Sadelain M. Honing CAR T cells to tackle acute myeloid leukemia. Blood. 2025;145(11):1113\u201325.","journal-title":"Blood"},{"issue":"8","key":"7151_CR144","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s43018-021-00241-5","volume":"2","author":"MC Milone","year":"2021","unstructured":"Milone MC, et al. Engineering enhanced CAR T-cells for improved cancer therapy. Nat Cancer. 2021;2(8):780\u201393.","journal-title":"Nat Cancer"},{"issue":"1","key":"7151_CR145","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12935-024-03315-3","volume":"24","author":"T Chen","year":"2024","unstructured":"Chen T, et al. Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors. Cancer Cell Int. 2024;24(1):133.","journal-title":"Cancer Cell Int"},{"key":"7151_CR146","first-page":"A129","volume":"9","author":"M Hosking","year":"2021","unstructured":"Hosking M, et al. 120 Chemokine receptor engineering enhances trafficking and homing of primary and iPSC-derived CAR-T cells to solid tumors. J Immunother Cancer. 2021;9:A129\u2013A129.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"7151_CR147","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s10238-025-01783-z","volume":"25","author":"M Abdar Esfahani","year":"2025","unstructured":"Abdar Esfahani M, et al. The epigenetic revolution in hematology: from benchside breakthroughs to clinical transformations. Clin Exp Med. 2025;25(1):230.","journal-title":"Clin Exp Med"},{"key":"7151_CR148","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117388","volume":"179","author":"KCS Pe","year":"2024","unstructured":"Pe KCS, et al. Optimization of anti-TIM3 chimeric antigen receptor with CD8\u03b1 spacer and TNFR-based costimulation for enhanced efficacy in AML therapy. Biomed Pharmacother. 2024;179:117388.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"7151_CR149","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s44313-024-00048-0","volume":"59","author":"R Hakak","year":"2024","unstructured":"Hakak R, Poopak B, Majd A. Increased IDO expression and regulatory T cells in acute myeloid leukemia: implications for immune escape and therapeutic targeting. Blood Res. 2024;59(1):42.","journal-title":"Blood Res"},{"issue":"12","key":"7151_CR150","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1111\/apm.13471","volume":"132","author":"M Yazdanpanah-Samani","year":"2024","unstructured":"Yazdanpanah-Samani M, et al. Anti-PD-L1 chimeric antigen receptor natural killer cell: characterization and functional analysis. APMIS. 2024;132(12):1115\u201327.","journal-title":"APMIS"},{"key":"7151_CR151","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.624742","volume":"11","author":"KK Wong","year":"2021","unstructured":"Wong KK, Hassan R, Yaacob NS. Hypomethylating agents and immunotherapy: therapeutic synergism in acute myeloid leukemia and myelodysplastic syndromes. Front Oncol. 2021;11:624742.","journal-title":"Front Oncol"},{"key":"7151_CR152","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115123","volume":"165","author":"X Lin","year":"2023","unstructured":"Lin X, et al. IPSC-derived CAR-NK cells for cancer immunotherapy. Biomed Pharmacother. 2023;165:115123.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"7151_CR153","doi-asserted-by":"publisher","first-page":"8439","DOI":"10.1038\/s41467-024-52388-1","volume":"15","author":"T Bexte","year":"2024","unstructured":"Bexte T, et al. CRISPR\/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells. Nat Commun. 2024;15(1):8439.","journal-title":"Nat Commun"},{"issue":"10","key":"7151_CR154","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.3324\/haematol.2017.187385","volume":"103","author":"BA Williams","year":"2018","unstructured":"Williams BA, et al. CD16(+)NK-92 and anti-CD123 monoclonal antibody prolongs survival in primary human acute myeloid leukemia xenografted mice. Haematologica. 2018;103(10):1720\u20139.","journal-title":"Haematologica"},{"issue":"2","key":"7151_CR155","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0294857","volume":"19","author":"S Lee","year":"2024","unstructured":"Lee S, et al. Successful expansion and cryopreservation of human natural killer cell line NK-92 for clinical manufacturing. PLoS ONE. 2024;19(2):e0294857.","journal-title":"PLoS ONE"},{"issue":"10","key":"7151_CR156","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.tibtech.2023.04.006","volume":"41","author":"M Khang","year":"2023","unstructured":"Khang M, et al. Manufacturing innovation to drive down cell therapy costs. Trends Biotechnol. 2023;41(10):1216\u20139.","journal-title":"Trends Biotechnol"},{"key":"7151_CR157","doi-asserted-by":"publisher","first-page":"1412378","DOI":"10.3389\/fimmu.2024.1412378","volume":"15","author":"X Wang","year":"2024","unstructured":"Wang X, et al. Scalable process development of NK and CAR-NK expansion in a closed bioreactor. Front Immunol. 2024;15:1412378.","journal-title":"Front Immunol"},{"key":"7151_CR158","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101136","volume":"63","author":"MS Odstrcil","year":"2024","unstructured":"Odstrcil MS, et al. Access to CAR T-cell therapy: focus on diversity, equity and inclusion. Blood Rev. 2024;63:101136.","journal-title":"Blood Rev"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07151-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07151-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07151-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T11:04:06Z","timestamp":1761217446000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-07151-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":158,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7151"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07151-5","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"assertion":[{"value":"30 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1163"}}